bullish

Novartis

Novartis AG: Positive Expectations for Scemblix & 5 Other Major Developments

184 Views30 Apr 2024 15:00
In Q1 2024, Novartis delivered robust growth, reflecting in a double-digit sales growth and core margin expansion. Sales were up by 11% in...
What is covered in the Full Insight:
  • Q1 2024 Performance
  • Guidance Upgrade
  • Innovation Milestones
  • DCF Valuation Methodology
  • Sensitivity Analysis/Scenario Analysis
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 46-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Baptista Research
Independent research on the U.S. markets
Baptista Research
United StatesEquity Bottom-UpEquity Capital Markets
Price Chart(Sign Up to Access)
analytics-chart
  • Novartis AG: Positive Expectations for Scemblix & 5 Other Major Developments
    30 Apr 2024
x